SHIP Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Established in 2017 and based in Suzhou, China, SHIP is a biotechnology company that focuses on the research and development of vaccines and biomedical products. The consulting team has over 20 years of experience in innovative vaccine basic research. In November 2018, SHIP closed a series A funding. In 2021, the industrial base was in construction. In 2023, the Phase III clinical trial of YD101 was started. The company is committed to the development and industrialization of innovative human vaccines and biopharmaceutical products and has developed five R&D technology platforms such as recombinant protein antigen vaccine, peptide polysaccharide conjugate vaccine, and so on. The company's pipeline includes more than ten preventive and therapeutic vaccine products which cover children's vaccines and adult vaccines.

Current Investors

NLVC, Lilly Asia Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy

Website

www.immune-path.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.